Search

Your search keyword '"paola gaviani"' showing total 2 results
Start Over Author "paola gaviani" Journal cns oncology
2 results on '"paola gaviani"'

1. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study

Author

Raffaele Addeo, Giuseppe Lamberti, Giorgia Simonetti, Patrizia Iodice, Alfredo Marinelli, Liliana Montella, Salvatore Cappabianca, Paola Gaviani, Michele Caraglia, Salvatore Del Prete, and Antonio Silvani

Subjects
alkylating, elderly, fotemustine, glioblastoma, high-grade glioma, nitrosourea, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Aim: To assess the efficacy and safety of alternative fotemustine administration schedule in elderly patients with recurrent glioblastoma. Patients & methods: Patients aged >65 years with recurrent glioblastoma received fotemustine (80 mg/m2; days 1, 15, 30, 45 and 60, and subsequently every 4 weeks). Primary end point was progression-free survival (PFS) rate at 6 months. Main secondary end point was safety. Results: 58 patients were enrolled at two centers. PFS at 6 months was 47% (27 patients) and overall response rate was 29%. Median PFS and survival were 6 and 7 months, respectively, and longer in responders versus nonresponders. No grade 3–4 hematological toxicities occurred. Conclusion: The alternative fotemustine administration schedule was an effective and safe treatment for recurrent glioblastoma in elderly patients.

Published
2019
Full Text
View/download PDF

2. Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study

Author

Michele Caraglia, Salvatore Del Prete, Paola Gaviani, Alfredo Marinelli, Liliana Montella, Antonio Silvani, Salvatore Cappabianca, Giuseppe Lamberti, Patrizia Iodice, Raffaele Addeo, Giorgia Simonetti, Marinelli, Alfredo, Addeo, Raffaele, Lamberti, Giuseppe, Simonetti, Giorgia, Iodice, Patrizia, Montella, Liliana, Cappabianca, Salvatore, Gaviani, Paola, Caraglia, Michele, Prete, Salvatore Del, and Silvani, Antonio

Subjects
Male, medicine.medical_specialty, Nitrosourea, nitrosourea, Antineoplastic Agents, Risk Assessment, elderly, Disease-Free Survival, Drug Administration Schedule, Nitrosourea Compounds, chemistry.chemical_compound, Organophosphorus Compounds, recurrent, Overall response rate, Internal medicine, Clinical endpoint, Humans, Medicine, Aged, End point, Brain Neoplasms, business.industry, Recurrent glioblastoma, Age Factors, glioblastoma, General Medicine, fotemustine, Survival Rate, alkylating, Multicenter study, chemistry, Toxicity, Fotemustine, Female, Neoplasm Recurrence, Local, business, high-grade glioma, Research Article, medicine.drug
Abstract

Aim: To assess the efficacy and safety of alternative fotemustine administration schedule in elderly patients with recurrent glioblastoma. Patients & methods: Patients aged >65 years with recurrent glioblastoma received fotemustine (80 mg/m2; days 1, 15, 30, 45 and 60, and subsequently every 4 weeks). Primary end point was progression-free survival (PFS) rate at 6 months. Main secondary end point was safety. Results: 58 patients were enrolled at two centers. PFS at 6 months was 47% (27 patients) and overall response rate was 29%. Median PFS and survival were 6 and 7 months, respectively, and longer in responders versus nonresponders. No grade 3–4 hematological toxicities occurred. Conclusion: The alternative fotemustine administration schedule was an effective and safe treatment for recurrent glioblastoma in elderly patients.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results